

Ding-Shinn Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336984/publications.pdf>

Version: 2024-02-01

595
papers

40,205
citations

2795

94
h-index

4323

173
g-index

601
all docs

601
docs citations

601
times ranked

21498
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
2	Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children. <i>New England Journal of Medicine</i> , 1997, 336, 1855-1859.	13.9	1,724
3	Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2002, 347, 168-174.	13.9	1,170
4	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	3.6	962
5	Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2000, 118, 554-559.	0.6	892
6	Global control of hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , The, 2002, 2, 395-403.	4.6	750
7	Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1134-1143.	3.0	549
8	Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1348-1355.	3.0	534
9	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	3.0	518
10	Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. <i>Gastroenterology</i> , 2003, 124, 327-334.	0.6	499
11	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18035.	18.1	490
12	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	0.6	469
13	Hepatitis B genotypes and the response to interferon therapy. <i>Journal of Hepatology</i> , 2000, 33, 998-1002.	1.8	449
14	Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. <i>Gastroenterology</i> , 1985, 89, 259-266.	0.6	400
15	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
16	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 167-228.	3.7	320
17	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	2.3	319
18	Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies. <i>Gastroenterology</i> , 2007, 132, 1287-1293.	0.6	314

#	ARTICLE	IF	CITATIONS
19	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005, 25, 472-489.	1.9	313
20	Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination. <i>Annals of Internal Medicine</i> , 2001, 135, 796.	2.0	311
21	An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17862-17867.	3.3	265
22	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	0.6	257
23	A Mass Vaccination Program in Taiwan Against Hepatitis B Virus Infection in Infants of Hepatitis B Surface Antigen Carrier Mothers. <i>JAMA - Journal of the American Medical Association</i> , 1987, 257, 2597.	3.8	250
24	MicroRNA-18a Prevents Estrogen Receptor- α Expression, Promoting Proliferation of Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2009, 136, 683-693.	0.6	250
25	Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. <i>Journal of Hepatology</i> , 2013, 59, 24-30.	1.8	227
26	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	3.6	227
27	Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. <i>Cancer</i> , 1985, 56, 660-666.	2.0	217
28	Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. <i>Journal of Hepatology</i> , 2009, 50, 805-816.	1.8	216
29	Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. <i>Hepatology</i> , 2015, 62, 375-386.	3.6	213
30	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	0.6	211
31	The Taiwanese hepatitis C virus genome: Sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. <i>Virology</i> , 1992, 188, 102-113.	1.1	210
32	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. <i>Journal of Hepatology</i> , 2015, 62, S76-S86.	1.8	198
33	Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, 1733-1738.	0.6	197
34	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	1.8	194
35	Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. <i>Journal of Medical Virology</i> , 1986, 18, 301-307.	2.5	192
36	Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. <i>Journal of Pediatrics</i> , 1995, 126, 589-591.	0.9	188

#	ARTICLE	IF	CITATIONS
37	Serum α -Fetoprotein in the Early Stage of Human Hepatocellular Carcinoma. <i>Gastroenterology</i> , 1984, 86, 1404-1409.	0.6	187
38	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , 2016, 151, 472-480.e1.	0.6	187
39	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	0.6	184
40	Minimization of hepatitis B infection by a 25-year universal vaccination program. <i>Journal of Hepatology</i> , 2012, 57, 730-735.	1.8	181
41	Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2005, 242, 36-42.	2.1	180
42	Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1207-1209.	1.8	178
43	Pegylated Interferon α 2a plus Ribavirin for Treatment of Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	2.9	177
44	Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15–18 Years after Neonatal Immunization. <i>Journal of Infectious Diseases</i> , 2008, 197, 1419-1426.	1.9	175
45	Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2175-2180.	3.3	175
46	Glycogen Synthase Kinase-3 Regulates the Phosphorylation of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein and Viral Replication. <i>Journal of Biological Chemistry</i> , 2009, 284, 5229-5239.	1.6	168
47	Possible Role of High-Titer Maternal Viremia in Perinatal Transmission of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 1994, 169, 638-641.	1.9	163
48	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	1.9	163
49	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 1648-1657.	6.1	161
50	Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. <i>Journal of Medical Virology</i> , 2004, 72, 363-369.	2.5	159
51	Prevention of Hepatocellular Carcinoma by Universal Vaccination against Hepatitis B Virus: The Effect and Problems. <i>Clinical Cancer Research</i> , 2005, 11, 7953-7957.	3.2	153
52	Serum α -fetoprotein in hepatocellular carcinoma. <i>Cancer</i> , 1977, 40, 779-783.	2.0	151
53	Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B. <i>Hepatology</i> , 2009, 50, 1392-1402.	3.6	151
54	Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4068-4071.	1.8	149

#	ARTICLE	IF	CITATIONS
55	Intrafamilial Transmission of Hepatitis C Virus: The Important Role of Infections between Spouses. <i>Journal of Infectious Diseases</i> , 1992, 166, 900-903.	1.9	148
56	Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 950-958.	1.0	143
57	Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma – a study based on 420 patients. <i>Journal of Hepatology</i> , 1996, 25, 334-338.	1.8	138
58	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	3.6	136
59	Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. <i>Journal of Pediatrics</i> , 1987, 111, 877-881.	0.9	135
60	Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC. <i>Cancer</i> , 1985, 56, 672-680.	2.0	134
61	Long-term Immunogenicity and Efficacy of Universal Hepatitis B Virus Vaccination in Taiwan. <i>Journal of Infectious Diseases</i> , 2003, 187, 134-138.	1.9	134
62	Hepatitis C and B viruses in hepatitis B Surface antigen-negative hepatocellular carcinoma. <i>Gastroenterology</i> , 1992, 103, 1322-1327.	0.6	133
63	Clonal Origin of Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 1989, 96, 527-529.	0.6	130
64	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	3.6	130
65	Cellular Immune Response to HBcAg in Mother-to-Infant Transmission of Hepatitis B Virus. <i>Hepatology</i> , 1992, 15, 770-776.	3.6	126
66	Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2571-2578.	3.3	126
67	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case-control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	1.9	125
68	Activation of Protooncogene C-jun by the X Protein of Hepatitis B Virus. <i>Virology</i> , 1993, 192, 346-350.	1.1	124
69	Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2542-2547.	3.3	121
70	Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. <i>International Journal of Cancer</i> , 2006, 119, 1946-1952.	2.3	120
71	Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12042-12047.	3.3	117
72	Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. <i>Hepatology</i> , 2004, 39, 58-63.	3.6	114

#	ARTICLE	IF	CITATIONS
73	Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1987, 5, 45-50.	1.8	113
74	Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. <i>Cancer</i> , 1989, 64, 2377-2380.	2.0	112
75	Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. <i>Cancer</i> , 1988, 61, 2095-2099.	2.0	111
76	Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: Multistage hepatocarcinogenesis with multifactorial etiology. <i>Hepatology</i> , 2002, 36, 1046-1049.	3.6	111
77	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	3.6	111
78	Plasma des-Î³-carboxyprothrombin in the early stage of hepatocellular carcinoma. <i>Hepatology</i> , 1990, 11, 481-487.	3.6	109
79	Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. <i>Proteomics</i> , 2006, 6, 2865-2873.	1.3	109
80	Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. <i>Journal of Pediatrics</i> , 1989, 115, 385-390.	0.9	108
81	The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age. <i>Hepatology</i> , 1995, 22, 1387-1392.	3.6	108
82	Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , 2006, 36, S33-S44.	1.6	105
83	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	1.8	105
84	Liver Resection Improves the Survival of Patients with Multiple Hepatocellular Carcinomas. <i>Annals of Surgical Oncology</i> , 2009, 16, 848-855.	0.7	105
85	Estrogen Receptor Î± Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4Î±. <i>Gastroenterology</i> , 2012, 142, 989-998.e4.	0.6	105
86	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	6.1	105
87	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	3.6	103
88	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002, 36, 303-304.	1.8	102
89	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	1.9	100
90	Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. <i>Journal of Pediatrics</i> , 2001, 139, 349-352.	0.9	99

#	ARTICLE	IF	CITATIONS
91	OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. <i>Nucleic Acids Research</i> , 2007, 35, D727-D731.	6.5	99
92	Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. <i>Liver International</i> , 2005, 25, 696-703.	1.9	98
93	Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. <i>Hepatology</i> , 2012, 56, 632-643.	3.6	98
94	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	2.8	98
95	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , 2005, 128, 708-716.	0.6	97
96	Determination of immune memory to hepatitis B vaccination through early booster response in college students. <i>Hepatology</i> , 2010, 51, 1547-1554.	3.6	97
97	Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. <i>Hepatology</i> , 2014, 60, 807-814.	3.6	97
98	Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: Five years after a mass hepatitis B vaccination program. <i>Journal of Medical Virology</i> , 1991, 34, 96-99.	2.5	95
99	Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3 β kinase pathways. <i>Hepatology</i> , 2009, 49, 1515-1524.	3.6	95
100	Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. <i>Gastroenterology</i> , 1993, 105, 583-587.	0.6	93
101	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α 2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	0.6	91
102	Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	2.0	91
103	$\hat{\Gamma}$ Agent Infection in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma-An Infrequent Finding in Taiwan. <i>Hepatology</i> , 1984, 4, 502-503.	3.6	89
104	Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 976-985.	0.2	89
105	Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors. <i>Surgery</i> , 1996, 120, 23-29.	1.0	88
106	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 779-782.	1.4	88
107	Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. <i>Journal of Hepatology</i> , 2000, 33, 791-798.	1.8	87
108	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. <i>Gastroenterology</i> , 1994, 107, 1514-1518.	0.6	86

#	ARTICLE	IF	CITATIONS
109	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	1.9	86
110	Recent Advances in the Research of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Advances in Cancer Research</i> , 2010, 108, 21-72.	1.9	86
111	Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. <i>Hepatology</i> , 1990, 12, 657-660.	3.6	84
112	Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. <i>Journal of Hepatology</i> , 1987, 5, 260-267.	1.8	83
113	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	83
114	GBV-C in the aetiology of fulminant hepatitis. <i>Lancet</i> , The, 1996, 347, 120-121.	6.3	83
115	Clinical and Virological Aspects of Blood Donors Infected with Hepatitis B Virus Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 22-25.	1.8	83
116	Increased Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients With Newly Diagnosed Diabetes: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1695-1702.	2.9	83
117	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	0.6	83
118	Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases. <i>Journal of Virology</i> , 2010, 84, 3454-3463.	1.5	81
119	Fulminant hepatitis in children in Taiwan: The important role of hepatitis B virus. <i>Journal of Pediatrics</i> , 1987, 111, 34-39.	0.9	80
120	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	0.6	80
121	Hepatitis B vaccination in children: The Taiwan experience. <i>Pathologie Et Biologie</i> , 2010, 58, 296-300.	2.2	80
122	Hepatocellular carcinoma in Taiwan. <i>Hepatology Research</i> , 2007, 37, S101-5.	1.8	79
123	Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. <i>Hepatology</i> , 1992, 15, 382-386.	3.6	77
124	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	2.2	77
125	Isoprenylation of Large Hepatitis Delta Antigen Is Necessary but Not Sufficient for Hepatitis Delta Virus Assembly. <i>Virology</i> , 1994, 199, 169-175.	1.1	76
126	Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. <i>Transfusion</i> , 2002, 42, 1592-1597.	0.8	76

#	ARTICLE	IF	CITATIONS
127	Epidemiologic Features of Kawasaki Disease in Taiwan, 1996-2002. <i>Pediatrics</i> , 2004, 114, e678-e682.	1.0	76
128	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	1.4	76
129	Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses. <i>Journal of Medical Virology</i> , 1992, 36, 28-31.	2.5	75
130	Hepatitis B Virus Infection and Hepatocellular Carcinoma: Molecular Genetics and Clinical Perspectives. <i>Seminars in Liver Disease</i> , 1999, 19, 253-262.	1.8	75
131	Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. <i>Hepatology</i> , 2001, 34, 817-823.	3.6	73
132	Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1324-1330.	2.4	73
133	Viremia Profiles in Children With Chronic Hepatitis B Virus Infection and Spontaneous e Antigen Seroconversion. <i>Gastroenterology</i> , 2007, 132, 2340-2345.	0.6	72
134	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients. <i>European Journal of Cancer</i> , 2009, 45, 1630-1639.	1.3	72
135	Toward elimination and eradication of hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 19-25.	1.4	72
136	Mixed Infections Of Hepatitis C Virus As A Factor In Acute Exacerbations Of Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1994, 170, 1128-1133.	1.9	71
137	Pegylated interferon α -2a versus standard interferon α -2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	6.1	69
138	Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9340-9345.	3.3	69
139	Transmission of hepatitis C virus in Asia: past and present perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E91-E96.	1.4	69
140	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003, 124, 80-90.	0.6	68
141	Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005, 25, 564-570.	1.9	68
142	Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. <i>European Journal of Cancer</i> , 2006, 42, 2524-2529.	1.3	67
143	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	6.1	67
144	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	1.9	67

#	ARTICLE	IF	CITATIONS
145	Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. <i>Journal of Medical Virology</i> , 1990, 32, 257-260.	2.5	66
146	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	3.6	66
147	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. <i>Journal of Hepatology</i> , 2015, 63, 354-363.	1.8	66
148	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 480-490.	2.3	66
149	Hepatitis B Virus Infection, Its Sequelae, and Prevention in Taiwan. , 1987, , 71-80.		66
150	Structure-Based Mutational Analysis of the Hepatitis C Virus NS3 Helicase. <i>Journal of Virology</i> , 2001, 75, 8289-8297.	1.5	65
151	Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. <i>Liver International</i> , 2006, 26, 766-773.	1.9	65
152	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	3.3	65
153	Natural history of chronic hepatitis B virus infection: New light on an old story. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 470-475.	1.4	64
154	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 235-242.	1.8	64
155	Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor Vaccine. <i>Human Gene Therapy</i> , 2000, 11, 681-692.	1.4	62
156	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	1.8	62
157	Relationship of hepatitis b surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. <i>Cancer</i> , 1979, 44, 984-992.	2.0	61
158	Fighting against viral hepatitis: Lessons from Taiwan. <i>Hepatology</i> , 2011, 54, 381-392.	3.6	61
159	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	0.6	61
160	Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5971-5975.	3.3	60
161	Least microtransfusion from mother to fetus in elective cesarean delivery. <i>Obstetrics and Gynecology</i> , 1996, 87, 244-248.	1.2	60
162	Comparative Immunoproteomics of Identification and Characterization of Virulence Factors from <i>Helicobacter pylori</i> Related to Gastric Cancer. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1484-1496.	2.5	60

#	ARTICLE	IF	CITATIONS
163	Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. <i>Journal of Hepatology</i> , 1998, 28, 915-922.	1.8	59
164	The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. <i>Virology</i> , 2004, 319, 60-70.	1.1	59
165	A Defective Interference-Like Phenomenon of Human Hepatitis B Virus in Chronic Carriers. <i>Journal of Virology</i> , 1998, 72, 578-584.	1.5	59
166	Postpartum subsidence of hepatitis B viral replication in hbeag-positive carrier mothers. <i>Journal of Medical Virology</i> , 1989, 29, 1-6.	2.5	58
167	Identification and characterization of intrahepatic hepatitis b virus dna in hbsag-seronegative patients with chronic liver disease and hepatocellular carcinoma in Taiwan. <i>Hepatology</i> , 1990, 12, 575-581.	3.6	58
168	Multiple hepatocellular carcinomas at the early stage have different clonality. <i>Gastroenterology</i> , 1993, 105, 1471-1476.	0.6	58
169	Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. <i>Digestive Diseases and Sciences</i> , 1996, 41, 161-165.	1.1	58
170	Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 605-609.	1.4	58
171	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 209-221.	3.6	58
172	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	3.3	57
173	Î Infection in asymptomatic carriers of hepatitis B surface antigen: Low prevalence of Î activity and effective suppression of hepatitis B virus replication. <i>Hepatology</i> , 1988, 8, 1121-1124.	3.6	56
174	Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan. <i>Journal of Medical Virology</i> , 1992, 37, 108-112.	2.5	56
175	Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1561-1566.	1.4	56
176	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	3.3	56
177	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	1.0	56
178	Correlation of hepatocyte HBsAg expression with virus replication and liver pathology. <i>Hepatology</i> , 1988, 8, 749-754.	3.6	55
179	Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. <i>Liver International</i> , 2006, 26, 1087-1094.	1.9	55
180	Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2716-2723.	2.9	55

#	ARTICLE	IF	CITATIONS
181	Phylogenetic Analysis of GB Virus C: Comparison of Isolates from Africa, North America, and Taiwan. <i>Journal of Infectious Diseases</i> , 1996, 174, 410-413.	1.9	54
182	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. <i>Biochemical Pharmacology</i> , 1998, 55, 523-531.	2.0	54
183	Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1995, 172, 261-264.	1.9	53
184	Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9954.	1.6	53
185	Hepatitis C virus RNA in saliva of patients with post-transfusion hepatitis C infection. <i>Lancet, The</i> , 1991, 337, 48.	6.3	52
186	Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. <i>Cancer</i> , 1994, 73, 42-47.	2.0	52
187	Expressions of cancer-testis antigens in human hepatocellular carcinomas. <i>Cancer Letters</i> , 2001, 164, 189-195.	3.2	52
188	Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1097-1108.	3.2	52
189	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	1.4	51
190	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	1.9	51
191	Genotypes of Hepatitis C Virus in Taiwan and the Progression of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 233-237.	1.1	50
192	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	3.6	50
193	Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 2003, 69, 466-470.	2.5	50
194	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	2.4	50
195	Changing seroepidemiology of hepatitis A virus infection in Taiwan. <i>Journal of Medical Virology</i> , 1985, 17, 297-301.	2.5	49
196	Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1986, 3, 182-189.	1.8	49
197	Temporal profile of hepatitis C virus antibody and genome in infants born to mothers infected with hepatitis C virus but without human immunodeficiency virus coinfection. <i>Journal of Hepatology</i> , 1994, 20, 641-645.	1.8	49
198	Posttransfusion hepatitis C virus infection in children. <i>Journal of Pediatrics</i> , 1994, 124, 709-713.	0.9	49

#	ARTICLE	IF	CITATIONS
199	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , 2009, 3, 517-525.	1.9	49
200	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	1.9	49
201	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1200-1209.	1.9	49
202	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	1.8	49
203	Low-power laserthermia for the treatment of small hepatocellular carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1622-1627.	0.9	48
204	Prevalence and Implication of a Newly Identified Infectious Agent (SEN Virus) in Taiwan. <i>Journal of Infectious Diseases</i> , 2002, 185, 389-392.	1.9	48
205	Ribavirin Up-regulates the Activity of Double-stranded RNA-Activated Protein Kinase and Enhances the Action of Interferon- α against Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2007, 196, 425-434.	1.9	47
206	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	1.9	47
207	Towards the eradication of hepatitis B in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 1-9.	0.8	47
208	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	3.6	47
209	Somatosensory evoked potentials in subclinical portosystemic encephalopathy: A comparison with psychometric tests. <i>Hepatology</i> , 1998, 27, 357-361.	3.6	46
210	Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 815-820.	1.4	46
211	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	1.9	46
212	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	1.9	46
213	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	1.9	46
214	Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 653-659.	1.8	45
215	Hepatitis B virus infection, its sequelae, and prevention by vaccination. <i>Current Opinion in Immunology</i> , 2011, 23, 237-243.	2.4	45
216	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	1.9	45

#	ARTICLE	IF	CITATIONS
217	Icteric type hepatocellular carcinoma: Revisited 20 years later. <i>Journal of Gastroenterology</i> , 1998, 33, 53-56.	2.3	44
218	Hepatitis B vaccination: to boost or not to boost?. <i>Lancet, The</i> , 2005, 366, 1337-1338.	6.3	44
219	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44
220	Hepatitis C virus in a prospective study of posttransfusion non-A, non-B hepatitis in Taiwan. <i>Journal of Medical Virology</i> , 1990, 32, 83-86.	2.5	43
221	Minimal role of hepatitis C virus infection in childhood liver diseases in an area hyperendemic for hepatitis B infection. <i>Journal of Medical Virology</i> , 1993, 40, 322-325.	2.5	43
222	Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 626-632.	2.3	43
223	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	2.5	43
224	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.4	43
225	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	1.8	43
226	Prevalence and implication of TT virus infection: Minimal role in patients with non-A-E hepatitis in Taiwan. , 1999, 59, 307-312.		42
227	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	2.5	42
228	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	0.6	42
229	Prevention of Hepatitis B. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021493-a021493.	2.9	42
230	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
231	Pathology of chronic hepatitis b virus infection in children: With special reference to the intrahepatic expression of hepatitis B virus antigens. <i>Hepatology</i> , 1988, 8, 378-382.	3.6	41
232	Interferon α -2b with and without ribavirin in the treatment of hepatitis B e antigen α “positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	3.6	41
233	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	2.2	41
234	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	0.6	41

#	ARTICLE	IF	CITATIONS
235	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	41
236	Prevalence of hepatitis C viral infection in a community in Taiwan. <i>Journal of Hepatology</i> , 1993, 17, 192-198.	1.8	40
237	Long term clinical and virologic outcome of primary hepatitis C virus infection in childre. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 769-773.	1.1	40
238	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	1.4	40
239	The Conserved Serine 177 in the Delta Antigen of Hepatitis Delta Virus Is One Putative Phosphorylation Site and Is Required for Efficient Viral RNA Replication. <i>Journal of Virology</i> , 2001, 75, 9087-9095.	1.5	40
240	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	2.5	40
241	Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: Role of dendritic cells. <i>Journal of Medical Virology</i> , 2002, 66, 320-328.	2.5	40
242	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	2.5	40
243	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	1.9	40
244	Reduced Toll-Like Receptor 3 Expression in Chronic Hepatitis B Patients and Its Restoration by Interferon Therapy. <i>Antiviral Therapy</i> , 2013, 18, 877-884.	0.6	40
245	Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. <i>Hepatology</i> , 2019, 69, 498-512.	3.6	40
246	Bile Duct Hamartomas. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 608-611.	1.1	40
247	Hepatitis B Virus in the Colostra of HBeAg-Positive Carrier Mothers. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1993, 17, 207-210.	0.9	39
248	Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. <i>Journal of Medical Virology</i> , 2002, 68, 216-220.	2.5	39
249	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	2.3	39
250	Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 211-217.	1.0	39
251	Application of Hepatitis B Virus Genotyping and Phylogenetic Analysis in Intrafamilial Transmission of Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2005, 41, 1576-1581.	2.9	39
252	Natural Course and Treatment of Hepatitis D Virus Infection. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 869-881.	0.8	39

#	ARTICLE	IF	CITATIONS
253	Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e497-e507.	5.1	39
254	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	6.1	39
255	The Double-stranded RNA-activated Kinase, PKR, Can Phosphorylate Hepatitis D Virus Small Delta Antigen at Functional Serine and Threonine Residues. <i>Journal of Biological Chemistry</i> , 2002, 277, 33058-33067.	1.6	38
256	Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2004, 64, 3030-3036.	0.4	38
257	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	3.6	38
258	Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 427-432.	1.1	38
259	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , 2005, 104, 783-91.	0.8	38
260	Serum HBsAg, HBeAg, anti-HBe, and hepatitis B viral DNA in asymptomatic carriers in Taiwan. <i>Journal of Medical Virology</i> , 1986, 19, 87-94.	2.5	37
261	Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides. <i>Journal of Biomedical Science</i> , 1997, 4, 208-216.	2.6	37
262	Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3047-3049.	1.8	37
263	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor α in female hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 761-770.	2.3	37
264	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11937-11942.	3.3	37
265	Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1987, 4, 45-51.	1.8	36
266	Cytophotometric measurements of nuclear DNA content in hepatocellular carcinomas. <i>Hepatology</i> , 1987, 7, 330-332.	3.6	36
267	A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. <i>Journal of Hepatology</i> , 1994, 21, 244-249.	1.8	36
268	Intrafamilial transmission of hepatitis C virus in hemodialysis patients. <i>Journal of Medical Virology</i> , 1995, 45, 381-385.	2.5	36
269	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	2.9	36
270	Lymphocyte Antigen 6 Complex, Locus C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. <i>Hepatology</i> , 2019, 69, 2364-2380.	3.6	36

#	ARTICLE	IF	CITATIONS
271	Characterization of the Phosphorylated Forms and the Phosphorylated Residues of Hepatitis Delta Virus Delta Antigens. <i>Journal of Virology</i> , 1999, 73, 10540-10545.	1.5	36
272	Temporal aspects of major viral transcript expression in hep G2 cells transfected with cloned hepatitis B virus DNA: With emphasis on the X transcript. <i>Virology</i> , 1991, 185, 644-651.	1.1	35
273	Isolation of a complementary DNA fragment of hepatitis C virus in Taiwan revealed significant sequence variations compared with other isolates. <i>Hepatology</i> , 1991, 14, 73-78.	3.6	35
274	Chromosome 1p aberrations are frequent in human primary hepatocellular carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 102-106.	1.0	35
275	Long-term culture of hepatocytes from human adults. <i>Journal of Biomedical Science</i> , 1998, 5, 435-440.	2.6	35
276	HBV genotypes: Epidemiology and implications regarding natural history. <i>Current Hepatitis Reports</i> , 2006, 5, 5-13.	0.3	35
277	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	35
278	Fraternal hepatocellular carcinoma in young children in two families. <i>Cancer</i> , 1984, 53, 1807-1810.	2.0	34
279	Genotypes of hepatitis C virus in chronic liver disease in Taiwan. <i>Journal of Medical Virology</i> , 1994, 44, 234-236.	2.5	34
280	Local ablation vs. resection for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, 373-373.	3.6	34
281	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	34
282	The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	0.5	34
283	Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. <i>Hepatology</i> , 2020, 72, 2063-2076.	3.6	34
284	Posttransfusion hepatitis revisited by hepatitis C antibody assays and polymerase chain reaction. <i>Gastroenterology</i> , 1992, 103, 609-616.	0.6	33
285	A Hospital-Based Study on the use of Alternative Medicine in Patients with Chronic Liver and Gastrointestinal Diseases. <i>The American Journal of Chinese Medicine</i> , 2002, 30, 637-643.	1.5	33
286	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008, 2, 250-257.	1.9	33
287	Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14769-14774.	3.3	33
288	Depletion of β -catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18384-18389.	3.3	33

#	ARTICLE	IF	CITATIONS
289	New Insights into the Evolutionary Rate of Hepatitis B Virus at Different Biological Scales. <i>Journal of Virology</i> , 2015, 89, 3512-3522.	1.5	33
290	Detection of hepatitis B virus dna in hepatocellular carcinoma: Analysis by hybridization with subgenomic dna fragments. <i>Hepatology</i> , 1988, 8, 518-523.	3.6	32
291	Regression of Established Mouse Leukemia by GM-CSF-Transduced Tumor Vaccine: Implications for Cytotoxic T Lymphocyte Responses and Tumor Burdens. <i>Human Gene Therapy</i> , 1997, 8, 1843-1854.	1.4	32
292	Identification of the Functional Regions Required for Hepatitis D Virus Replication and Transcription by Linker-Scanning Mutagenesis of Viral Genome. <i>Virology</i> , 1997, 239, 119-131.	1.1	32
293	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	2.6	32
294	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997, 53, 348-353.	2.5	31
295	High frequency of expression of MAGE genes in human hepatocellular carcinoma. <i>Liver International</i> , 1999, 19, 110-114.	1.9	31
296	Genetic predisposition of responsiveness to therapy for chronic hepatitis C. <i>Pharmacogenomics</i> , 2006, 7, 697-709.	0.6	31
297	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	1.9	31
298	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	1.4	31
299	Fine mapping of hepatitis B virus pre- ϵ deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	1.9	31
300	Improved Serodiagnosis of Posttransfusion Hepatitis C Virus Infection by a Second-Generation Immunoassay Based on Multiple Recombinant Antigens. <i>Vox Sanguinis</i> , 1992, 62, 21-24.	0.7	30
301	Association of HLA-DR14 ϵ DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. <i>Vaccine</i> , 1993, 11, 1437-1440.	1.7	30
302	Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis B virus DNA in hepatocellular carcinomas. <i>Journal of Virological Methods</i> , 1994, 49, 269-284.	1.0	30
303	Mechanism of vertical transmission of hepatitis G. <i>Lancet, The</i> , 1996, 347, 1116.	6.3	30
304	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. , 1996, 77, 872-877.		30
305	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	30
306	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	1.3	30

#	ARTICLE	IF	CITATIONS
307	Historical epidemiology of hepatitis C virus in select countries volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 8-24.	1.0	30
308	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. <i>PLoS ONE</i> , 2013, 8, e81922.	1.1	30
309	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	0.6	30
310	Status of hepatitis B virus DNA in hepatocellular carcinoma: A study based on paired tumor and nontumor liver tissues. <i>Journal of Medical Virology</i> , 1988, 25, 249-258.	2.5	29
311	Hepatitis C virus infection in Taiwan. <i>Gastroenterologia Japonica</i> , 1991, 26, 164-166.	0.4	29
312	An ELISA for RNA Helicase Activity: Application as an Assay of the NS3 Helicase of Hepatitis C Virus. <i>Biochemical and Biophysical Research Communications</i> , 1998, 253, 594-599.	1.0	29
313	Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 320-328.	1.5	29
314	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	2.4	29
315	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	3.6	29
316	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	0.6	29
317	Chronic hepatitis B is associated with an increased risk of B cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	1.9	29
318	Taiwan commits to eliminating hepatitis C in 2025. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 466-467.	4.6	29
319	Non-A, non-B hepatitis in children: A clinical, histologic, and serologic study. <i>Journal of Medical Virology</i> , 1991, 35, 1-6.	2.5	28
320	TT virus infection in patients with chronic hepatitis B or C: Influence on clinical, histological and virological features. , 2000, 60, 387-392.		28
321	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	1.9	28
322	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	1.4	28
323	Molecular Cloning of cDNAs Corresponding to Two Genes of Î±1-Acid Glycoprotein and Characterization of Two Alleles of AGP-1 in the Mouse. <i>DNA and Cell Biology</i> , 1989, 8, 245-251.	5.1	27
324	Biologic significance of the detection of HBsAg and HBcAg in liver and tumor from 204 HBsAg-positive patients with primary hepatocellular carcinoma. <i>Hepatology</i> , 1989, 9, 747-750.	3.6	27

#	ARTICLE	IF	CITATIONS
325	Albumin messenger RNA is not specific for circulating hepatoma cells. <i>Gastroenterology</i> , 1994, 107, 630-631.	0.6	27
326	Amebic Liver Abscess and Human Immunodeficiency Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 64-68.	1.1	27
327	DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by Feulgen-DNA analysis. <i>Liver</i> , 1987, 7, 359-363.	0.1	27
328	Pegylated interferon α -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	6.1	27
329	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	1.4	27
330	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	2.9	27
331	Overview of Hepatitis B and C Viruses. , 0, , 313-330.		27
332	A prospective study of posttransfusion hepatitis in Taiwan. <i>Journal of Hepatology</i> , 1991, 13, 38-43.	1.8	26
333	Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 1991, 35, 237-240.	2.5	26
334	Low prevalence of hepatitis C virus infection among dentists in Taiwan. <i>Journal of Medical Virology</i> , 1993, 40, 10-13.	2.5	26
335	Hepatitis Delta Virus cDNA Monomer Can Be Used in Transfection Experiments to Initiate Viral RNA Replication. <i>Virology</i> , 1993, 197, 137-142.	1.1	26
336	Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 21, 403-411.	1.8	26
337	N-Linked Glycosylation of Hepatitis B Surface Antigens Is Involved but Not Essential in the Assembly of Hepatitis Delta Virus. <i>Virology</i> , 1996, 220, 28-36.	1.1	26
338	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 25-43.	1.0	26
339	Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. <i>Journal of Gene Medicine</i> , 2003, 5, 386-398.	1.4	25
340	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	2.5	25
341	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2015, 9, 231-242.	1.9	25
342	Complete Agenesis of the Dorsal Pancreas—A Case Report and Review of the Literature. <i>Pancreas</i> , 1990, 5, 493-497.	0.5	24

#	ARTICLE	IF	CITATIONS
343	Long-Term Expression of the Biologically Active Growth Hormone in Genetically Modified Fibroblasts after Implantation into a Hypophysectomized Rat. <i>Human Gene Therapy</i> , 1995, 6, 917-926.	1.4	24
344	Early acquisition of TT virus in infants: Possible minor role of maternal transmission. <i>Journal of Medical Virology</i> , 2002, 66, 285-290.	2.5	24
345	Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 682-689.	1.4	24
346	Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1627-1632.	1.1	24
347	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	1.9	24
348	Allelic loss of chromosome 4q21-23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	24
349	Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E7-E10.	1.4	24
350	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	2.5	23
351	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	0.6	23
352	Hepatitis B Virus Nucleocapsid but Not Free Core Antigen Controls Viral Clearance in Mice. <i>Journal of Virology</i> , 2012, 86, 9266-9273.	1.5	23
353	Genome-wide association analysis identifies a <i>GLUL</i> haplotype for familial hepatitis B virus-related hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3966-3976.	2.0	23
354	Cytogenetic studies on human liver cancer cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1993, 65, 161-166.	1.0	22
355	Quantitative detection of hepatitis B virus DNA in human sera by branched-DNA signal amplification. <i>Journal of Virological Methods</i> , 1995, 53, 131-137.	1.0	22
356	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	3.6	22
357	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	1.0	22
358	Clinical manifestations and survival of patients with hepatocellular carcinoma and cardiac metastasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 150-155.	1.4	22
359	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	0.8	22
360	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	1.6	22

#	ARTICLE	IF	CITATIONS
361	Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. <i>Cancer Research</i> , 2002, 62, 4346-51.	0.4	22
362	Geographical distribution of the subtype of hepatitis b surface antigen in chinese. <i>Gastroenterologia Japonica</i> , 1977, 12, 58-63.	0.4	21
363	Hepatitis D virus infection in children with acute or chronic hepatitis B virus infection in Taiwan. <i>Journal of Pediatrics</i> , 1988, 112, 888-892.	0.9	21
364	Detection of hepatitis B viral DNA by polymerase chain reaction in patients with hepatitis B surface antigen. <i>Journal of Medical Virology</i> , 1990, 30, 159-162.	2.5	21
365	Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 454-458.	1.4	21
366	Antibodies to E2 protein of hepatitis G virus in children: Different responses according to age at infection. <i>Journal of Pediatrics</i> , 1998, 133, 382-385.	0.9	21
367	Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. <i>Vaccine</i> , 2001, 19, 2825-2829.	1.7	21
368	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	1.9	21
369	Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2007, 120, 1610-1617.	2.3	21
370	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010, 4, 585-593.	1.9	21
371	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	1.0	21
372	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	1.6	21
373	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	1.0	21
374	Hepatitis C Viral Infection in Thalassemic Children: Clinical and Molecular Studies. <i>Pediatric Research</i> , 1996, 39, 323-328.	1.1	21
375	Serum α -Fetoprotein Levels in Normal Infants. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1989, 8, 19-25.	0.9	20
376	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. <i>Journal of Biomedical Science</i> , 1998, 5, 180-184.	2.6	20
377	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	1.9	20
378	Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. <i>Gastroenterology</i> , 2003, 125, 1916-1917.	0.6	20

#	ARTICLE	IF	CITATIONS
379	SEN Virus Infection in Patients with Chronic Hepatitis C: Preferential Coinfection with Hepatitis C Genotype 2a and No Effect on Response to Therapy with Interferon plus Ribavirin. <i>Journal of Infectious Diseases</i> , 2003, 187, 307-310.	1.9	20
380	Long-Term Protection of Hepatitis B Vaccine: Lessons from Alaskan Experience after 15 Years. <i>Annals of Internal Medicine</i> , 2005, 142, 384.	2.0	20
381	Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. <i>Genes and Immunity</i> , 2009, 10, 27-36.	2.2	20
382	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus-Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	1.1	20
383	Clinical Impact of Screening First-Degree Relatives of Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 236-239.	1.1	20
384	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. <i>Liver International</i> , 2003, 23, 426-433.	1.9	19
385	Epigenetic activation of β 4, β 2 and β 6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. <i>Journal of Biomedical Science</i> , 2005, 12, 803-813.	2.6	19
386	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	1.9	19
387	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	1.1	19
388	Sorafenib Action in Hepatitis B Virus-Activated Oncogenic Androgen Pathway in Liver through SHP-1. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv190.	3.0	19
389	Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 306-316.	1.9	19
390	Delta-agent infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 1-8.	1.4	18
391	Absence or delayed appearance of hepatitis B core antibody in chronic hepatitis B surface antigen carrier children. <i>Journal of Hepatology</i> , 1993, 17, 150-154.	1.8	18
392	Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: Correlation with genotypes. <i>Journal of Gastroenterology</i> , 1996, 31, 224-227.	2.3	18
393	Characteristics of hepatocellular carcinoma presenting with variceal bleeding. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 170-174.	1.4	18
394	Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2002, 97, 269-271.	2.3	18
395	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	1.9	18
396	Peginterferon α in the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 995-1006.	1.4	18

#	ARTICLE	IF	CITATIONS
397	Reduced Toll-Like Receptor 9 Expression on Peripheral CD14 ⁺ Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy. <i>Antiviral Therapy</i> , 2014, 19, 637-643.	0.6	18
398	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	0.4	18
399	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	3.6	18
400	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1187-1192.	0.8	18
401	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	1.1	18
402	Inadequacy of Immunoglobulin M hepatitis B core antibody in detecting acute hepatitis B virus infection in infants of HBsAg carrier mothers. <i>Journal of Medical Virology</i> , 1985, 16, 309-314.	2.5	17
403	Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. <i>Journal of Hepatology</i> , 2003, 39, 1028-1035.	1.8	17
404	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	1.2	17
405	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	1.3	17
406	Chronologic changes in serum hepatitis B virus <scp>DNA</scp>, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan. <i>Journal of Viral Hepatitis</i> , 2017, 24, 645-653.	1.0	17
407	Strategies to manage hepatitis C virus infection disease burden—Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 44-63.	1.0	17
408	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	4.2	17
409	Sexual transmission of HCV. <i>Lancet, The</i> , 1993, 342, 626.	6.3	16
410	Portal blood flow in acute hepatitis with and without ascites: A non-invasive measurement using an ultrasonic Doppler. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 36-41.	1.4	16
411	Alcoholism, Hepatitis B and C Viral Infections, and Impaired Liver Function among Taiwanese Aboriginal Groups. <i>American Journal of Epidemiology</i> , 1996, 143, 936-942.	1.6	16
412	A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. <i>Cancer Causes and Control</i> , 1996, 7, 305-311.	0.8	16
413	Molecular biology of hepatitis D virus: Research and potential for application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S188-S192.	1.4	16
414	Comparison of two methods for quantification of hepatitis B viral DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 423-426.	1.4	16

#	ARTICLE	IF	CITATIONS
415	Role of zinc in subclinical hepatic encephalopathy: Comparison with somatosensory-evoked potentials. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 375-379.	1.4	16
416	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 859-862.	1.4	16
417	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	1.0	16
418	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	1.4	16
419	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	1.4	16
420	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	1.4	15
421	Identification of Humoral Antigenic Determinants in the Hepatitis C Virus NS3 Protein. <i>Journal of Infectious Diseases</i> , 1996, 174, 173-176.	1.9	14
422	Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, 511-517.	1.0	14
423	Ribavirin Enhances Interferon- γ ; Levels in Patients with Chronic Hepatitis C Treated with Interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	14
424	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004, 24, 9-15.	1.9	14
425	Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: Mechanisms for the superior antitumor activity of live tumor cell vaccines. <i>Journal of Biomedical Science</i> , 2004, 11, 228-238.	2.6	14
426	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	1.0	14
427	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	1.9	14
428	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	1.9	14
429	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	2.3	14
430	No more excuses: viral hepatitis can be eliminated. <i>Lancet, The</i> , 2016, 387, 1703-1704.	6.3	14
431	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	0.8	14
432	De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. <i>BMC Bioinformatics</i> , 2017, 18, 223.	1.2	14

#	ARTICLE	IF	CITATIONS
433	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	0.8	14
434	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	1.4	14
435	HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. <i>Journal of Biomedical Science</i> , 2020, 27, 70.	2.6	14
436	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	1.4	14
437	Noninvasive Diagnosis of Advanced Pancreatic Cancer by Real-Time Ultrasonography, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9. <i>Pancreas</i> , 1986, 1, 219-223.	0.5	13
438	Effects of GB virus-C/hepatitis G virus on hepatitis B and C viremia in multiple hepatitis virus infections. <i>Archives of Virology</i> , 1998, 143, 797-802.	0.9	13
439	Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 705-708.	1.4	13
440	Universal Hepatitis B Vaccination: Killing 2 Birds with 1 Stone. <i>American Journal of Medicine</i> , 2008, 121, 1029-1031.	0.6	13
441	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	1.9	13
442	Ribavirin Enhances the Action of Interferon- α against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway. <i>PLoS ONE</i> , 2012, 7, e43824.	1.1	13
443	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	1.6	13
444	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	1.6	13
445	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	1.1	13
446	Taiwan is on track of accelerating hepatitis C elimination by 2025. <i>Liver International</i> , 2020, 40, 1506-1507.	1.9	13
447	Recent research progress in hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2002, 101, 239-48.	0.8	13
448	HBeAg and anti-HBe in chronic hepatitis B virus infection. <i>Gastroenterology</i> , 1981, 80, 880-881.	0.6	12
449	Evolution of expression of hepatitis B surface and core antigens (HBsAg, HBcAg) in resected primary and recurrent hepatocellular carcinoma in HBsAg carriers in Taiwan. Correlation with local host immune response. <i>Cancer</i> , 1988, 62, 915-921.	2.0	12
450	Pancreatic Carcinoma Associated With Chronic Calcifying Pancreatitis in Taiwan. <i>Pancreas</i> , 1988, 3, 111-114.	0.5	12

#	ARTICLE	IF	CITATIONS
451	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease?. <i>Journal of Biomedical Science</i> , 1999, 6, 220-225.	2.6	12
452	A forgotten population with chronic hepatitis C infection: Subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , 2004, 40, 266-266.	3.6	12
453	Selective Transmission of Hepatitis C Virus Quasi Species through a Needlestick Accident in Acute Resolving Hepatitis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1254-1259.	2.9	12
454	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	1.9	12
455	Feedback regulation of IFN α /IFN β signaling by Axl receptor tyrosine kinase modulates HBV immunity. <i>European Journal of Immunology</i> , 2015, 45, 1696-1705.	1.6	12
456	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	0.6	12
457	Hepatitis D virus infection among intravenous drug abusers in Taiwan: Analysis of risk factors and liver function tests. <i>Journal of Medical Virology</i> , 1990, 31, 76-81.	2.5	11
458	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11
459	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11
460	Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C. <i>Clinical and Experimental Immunology</i> , 1995, 101, 272-277.	1.1	11
461	GBV-C/HGV infection and aplastic anaemia. <i>Lancet, The</i> , 1996, 348, 1032-1033.	6.3	11
462	Assembly of Hepatitis Delta Virus-like Empty Particles in Yeast. <i>Virology</i> , 1997, 236, 374-381.	1.1	11
463	Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. <i>Archives of Virology</i> , 1999, 144, 2173-2183.	0.9	11
464	Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens. <i>Vaccine</i> , 1999, 17, 26-30.	1.7	11
465	Efficacy of consensus interferon in the treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1418-1423.	1.4	11
466	Characterization of cytokeratin 19-positive hepatocyte foci in the regenerating rat liver after 2-AAF/CCl4 injury. <i>Histochemistry and Cell Biology</i> , 2007, 128, 217-226.	0.8	11
467	Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. <i>Hepatology International</i> , 2009, 3, 537-543.	1.9	11
468	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016, 6, 32303.	1.6	11

#	ARTICLE	IF	CITATIONS
469	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	1.9	11
470	Profile and value of FIB4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	1.4	11
471	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	1.9	11
472	Natural history of hepatitis B surface antigen-positive cirrhosis in Taiwan: A clinicopathological study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1988, 3, 583-592.	1.4	10
473	Improved gene expression by a U3-based retroviral vector. <i>Biochemical and Biophysical Research Communications</i> , 1992, 184, 330-337.	1.0	10
474	Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 338-341.	1.4	10
475	The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age*1. <i>Hepatology</i> , 1995, 22, 1387-1392.	3.6	10
476	Rapid hepatic failure associated with a contracted liver mimicking cirrhosis in a case of nasopharyngeal carcinoma with liver metastasis. <i>Liver</i> , 1996, 16, 283-287.	0.1	10
477	Pegylated IFN- α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14799-14804.	3.3	10
478	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	10
479	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	0.6	10
480	Hepatitis B e antigen and its antibody in chronic type B hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 255-270.	1.4	9
481	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. <i>Journal of Biomedical Science</i> , 1998, 5, 290-296.	2.6	9
482	Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: implications for occupational health practice. <i>Occupational and Environmental Medicine</i> , 1999, 56, 730-734.	1.3	9
483	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. <i>Journal of Medical Virology</i> , 2001, 65, 567-575.	2.5	9
484	Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. <i>Gastroenterology</i> , 2006, 131, 1656.	0.6	9
485	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	0.6	9
486	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	3.6	9

#	ARTICLE	IF	CITATIONS
487	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6717-6725.	3.3	9
488	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	2.6	9
489	Characterization of T cell clones specific to a determinant of hepatitis B virus core and e antigens in chronic type B hepatitis: Implication for a T cell mechanism of HBV immunopathogenesis. <i>Journal of Biomedical Science</i> , 1994, 1, 105-118.	2.6	8
490	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon alpha alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1249-1253.	1.4	8
491	Mixed hepatitis B virus genotype infections: The more, the worse?. <i>Hepatology</i> , 2006, 44, 770-770.	3.6	8
492	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 816-821.	0.8	8
493	Biphasic Pattern of Depression and Its Predictors during Pegylated Interferon-Based Therapy in Chronic Hepatitis B and C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-7.	0.6	8
494	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 716-721.	0.8	8
495	We Have Never Been Latecomers: A Critical Review of High-Tech Industry and Social Studies of Technology in Taiwan. <i>East Asian Science, Technology and Society</i> , 2015, 9, 381-396.	0.2	8
496	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
497	From the big three to the big four. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 626-627.	4.6	8
498	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	1.6	8
499	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	8
500	Serum Hepatitis C Virus Titers in the Progression of Type C Chronic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 280-283.	1.1	8
501	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-480.	0.6	8
502	Structure and Expression of Mouse Î±1-Acid Glycoprotein Gene-3 (AGP-3). <i>DNA and Cell Biology</i> , 1992, 11, 315-320.	0.9	7
503	Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: Different antigenic determinants from human B cells. , 1999, 57, 345-350.		7
504	Ribavirin enhances interferon-Î³ levels in patients with chronic hepatitis C treated with interferon-Î±. <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	7

#	ARTICLE	IF	CITATIONS
505	HBV genotypes and outcome of HBV infection. <i>Hepatology</i> , 2005, 41, 216-216.	3.6	7
506	Caput Medusae. <i>New England Journal of Medicine</i> , 2005, 353, e19.	13.9	7
507	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007, 27, 235-239.	1.9	7
508	Age-specific Prevalence of Hepatitis B Surface and e Antigenemia in Pregnant Women in Taiwan. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 141-145.	0.0	7
509	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	1.4	7
510	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
511	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	1.9	7
512	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	1.4	7
513	The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1444-1451.	0.8	7
514	Multiple variants in UGT1A1 gene are factors to develop indirect hyper-bilirubinemia. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 194-8.	0.7	7
515	Pleural effusion coinciding with acute exacerbations in a patient with chronic hepatitis B. <i>Gastroenterology</i> , 1989, 96, 1604-1606.	0.6	6
516	Prognostic Implications of Serum α -Fetoprotein Levels in Neonatal Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1990, 11, 27-31.	0.9	6
517	Recombinant immunoblot assay for hepatitis C antibody in patients with posttransfusion non-A, non-B hepatitis. <i>Journal of Medical Virology</i> , 1991, 34, 172-175.	2.5	6
518	Functional Measurement of Hepatitis C Virus Core-Specific CD8 + T-Cell Responses in the Livers or Peripheral Blood of Patients by Using Autologous Peripheral Blood Mononuclear Cells as Targets or Stimulators. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3895-3901.	1.8	6
519	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1311-1311.	3.6	6
520	A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 149-151.	1.3	6
521	Allelic loss of chromosome 4q21 α -23 associates with hepatitis B Virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	6
522	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	2.5	6

#	ARTICLE	IF	CITATIONS
523	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	1.9	6
524	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	0.8	6
525	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	1.9	6
526	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	6
527	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	0.6	6
528	Fulminant hepatitis in infants in Taiwan: Strong association with hepatitis B e antigen-negative but antibody-positive maternal hepatitis B surface antigen carriage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1988, 3, 1-7.	1.4	5
529	Characterization of the Transcripts of Hepatitis D and B Viruses in Infected Human Livers. <i>Journal of Infectious Diseases</i> , 1989, 160, 944-947.	1.9	5
530	Mother-to-child HCV transmission. <i>Lancet, The</i> , 2001, 357, 142-143.	6.3	5
531	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	0.6	5
532	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	2.3	5
533	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	0.8	5
534	Persistence of IgM hepatitis A antibody after clinical type A hepatitis. <i>Hepatology</i> , 1985, 5, 705-705.	3.6	4
535	Carcinoma of the Gallbladder from an Anomalous Connection between the Bile Duct and the Pancreatic Duct. <i>Journal of Clinical Gastroenterology</i> , 1988, 10, 335-338.	1.1	4
536	Laserthermia for the Treatment of Small Hepatocellular Carcinoma: A Preliminary Study. <i>Photomedicine and Laser Surgery</i> , 1991, 9, 195-197.	1.1	4
537	Early Interferon Therapy and Abortion of Posttransfusion Hepatitis C Viral Infection. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 38-41.	1.1	4
538	Prevalence, Genotypes and Antibody Titer of Hepatitis C Virus in Pregnant Women in Taiwan. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995, 21, 557-562.	0.1	4
539	Taiwan's Antinuclear Movement in the Wake of the Fukushima Disaster, Viewed from an STS Perspective. <i>East Asian Science, Technology and Society</i> , 2011, 5, 567-572.	0.2	4
540	Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China. <i>Hepatology</i> , 2016, 64, 1008-1009.	3.6	4

#	ARTICLE	IF	CITATIONS
541	Taiwan's health-care system and administration are independent of China. <i>Lancet, The</i> , 2019, 394, 1516.	6.3	4
542	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	1.4	4
543	Hepatitis B and C Virus Infections in Hepatocellular Carcinoma and Their Prevention. , 1994, , 685-689.		4
544	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- κ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	0.8	4
545	Induction of an alu-sequence containing transcript by insulin in human hepatoma cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 156, 1287-1292.	1.0	3
546	Acute Jejuno gastric Intussusceptionâ€”A Case Report. <i>Digestive Endoscopy</i> , 1993, 5, 404-408.	1.3	3
547	Detection of divergent hepatitis C virus envelope sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	2.6	3
548	CASE REPORT: Successful palliative treatment with intraperitoneal OK-432 injection for epithelioid haemangioendothelioma presenting with intractable ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 39-43.	1.4	3
549	Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006, 4, 157-167.	0.3	3
550	Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. <i>Current Hepatitis Reports</i> , 2008, 7, 5-11.	0.3	3
551	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.4	3
552	Essential components in developing public policy to control viral hepatitis: lessons from Taiwan. <i>Hepatology International</i> , 2016, 10, 355-362.	1.9	3
553	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.1	3
554	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. , 1998, 5, 180.		3
555	Metastatic tumor antigen 1 contributes to hepatocarcinogenesis posttranscriptionally through RNAâ€”binding function. <i>Hepatology</i> , 2023, 77, 379-394.	3.6	3
556	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-80.	0.6	3
557	Changing aetiologic patterns of acute viral hepatitis in Taiwanese children. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989, 4, 339-344.	1.4	2
558	Improved Serodiagnosis of Posttransfusion Hepatitis C Virus Infection by a Second-Generation Immunoassay Based on Multiple Recombinant Antigens. <i>Vox Sanguinis</i> , 1992, 62, 21-24.	0.7	2

#	ARTICLE	IF	CITATIONS
559	Characterization of T Cell Clones Specific to a Determinant of Hepatitis B Virus Core and e Antigens in Chronic Type B Hepatitis: Implication for a T Cell Mechanism of HBV Immunopathogenesis. <i>Journal of Biomedical Science</i> , 1994, 1, 105-118.	2.6	2
560	Evaluation of Third-Generation Hepatitis C Antibody Assay in Chronic Hepatitis C and Chronic Non-B, Non-C Hepatitis. <i>Viral Immunology</i> , 1995, 8, 135-139.	0.6	2
561	Clinical Significance of Occult Hepatitis B Virus Infection Cannot Be Overlooked. <i>Clinical Infectious Diseases</i> , 2006, 42, 583-584.	2.9	2
562	Hepatitis C Virus Infection in Pregnant Women: Detection by Different Anti-HCV Immunoassays and Serum HCV RNA. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 13-18.	0.0	2
563	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	1.9	2
564	Microevolution of the hepatitis B virus genome in hepatitis B antigen-positive carriers: Comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	1.4	2
565	Reduced doses of hepatitis B immune globulin in the prevention of perinatal transmission of hepatitis B. <i>Journal of Medical Virology</i> , 1987, 21, 301-309.	2.5	1
566	Immunoglobulin M antibodies against hepatitis C virus antigens: significance and applications. <i>Gastroenterologia Japonica</i> , 1993, 28, 67-70.	0.4	1
567	Title is missing!. <i>Journal of Pediatrics</i> , 1995, 127, 671.	0.9	1
568	An oath for bioscientists. <i>Journal of Biomedical Science</i> , 2003, 10, 569-576.	2.6	1
569	Hepatitis B virus genotypes and core promoter variant. <i>Gastroenterology</i> , 2004, 126, 633.	0.6	1
570	Acute rhabdomyolysis and chylous ascites in a patient with cirrhosis and malignant hepatic tumor. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 137-138.	0.8	1
571	Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1382-1395.	0.8	1
572	Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. , 1994, 73, 42.		1
573	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. , 1998, 5, 290.		1
574	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease?. , 1999, 6, 220.		1
575	An oath for bioscientists. <i>Journal of Biomedical Science</i> , 2003, 10, 569-76.	2.6	1
576	Delta agent in nondrug addicts. <i>Hepatology</i> , 1985, 5, 526-528.	3.6	0

#	ARTICLE	IF	CITATIONS
577	Studies on duck hepatitis B virus: Identification and epidemiological survey in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 1987, 2, 423-429.	1.4	0
578	Laserthermia for the treatment of small hepatocellular carcinoma: a preliminary study. , 1990, 1201, 620.		0
579	Detection of Divergent Hepatitis C Virus Envelope Sequences. Journal of Biomedical Science, 1994, 1, 158-162.	2.6	0
580	Reply to de Sio et al.. Journal of Hepatology, 1997, 26, 1156.	1.8	0
581	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1287-1291.	1.4	0
582	Prevention of hepatocellular carcinoma by hepatitis B immunization. Perspectives in Medical Virology, 2002, 6, 143-150.	0.1	0
583	Taiwan as a Clinical Trial Center of Excellence in the Asia Pacific. Asia Pacific Biotech News, 2007, 11, 841-844.	0.5	0
584	APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers. Hepatology, 2007, 45, 1586-1587.	3.6	0
585	STS and Area Studies: A Social Network Perspective. East Asian Science, Technology and Society, 2008, 2, 439-444.	0.2	0
586	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. American Journal of Gastroenterology, 2008, 103, 2663-2665.	0.2	0
587	Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease. Hepatology, 2009, 50, 989-989.	3.6	0
588	Hepatitis B vaccine and multiple sclerosis: A case of repeated dÃ©jÃ© vu?. Journal of Hepatology, 2009, 51, 598-599.	1.8	0
589	Hepatitis B and Deltavirus Infections. , 2011, , 433-440.		0
590	Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E303-E303.	3.3	0
591	Corrigendum to: "Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia" [Hepatology 2013;59:1073-1080]. Journal of Hepatology, 2014, 60, 902-903.	1.8	0
592	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1287-1291.	1.4	0
593	Treatment of Hepatitis C Virus Infection: Past, Present and Future. , 2012, , 341-371.		0
594	Hepatitis B Virus: Pathogenesis and Host Immune Response. , 2014, , 113-132.		0

#	ARTICLE	IF	CITATIONS
595	Serial Follow-up of Hepatitis C Virus RNA and Antibody in Infants Born to Hepatitis C Virus Positive but Human Immunodeficiency Virus Negative Mothers. , 1994, , 471-473.		0